Standardized Antihypertensive Treatment Protocol

NCT06790927 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai Jiao Tong University School of Medicine

Phase

Not applicable

Started

2025-02-24

Last updated

2025-01-24

Condition(s) studied

Hypertension

Investigational drug(s) / intervention(s)

Usual CareStandard Medical Therapy →

Usual Care: The doctor prescribes medication for patients and follow-up every 3 months

Standard Medical Therapy: The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks treatment, amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets after one month, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.

Study summary

Study name: A cluster randomized controlled trial on a standardized antihypertensive treatment protocol.

Objective: To evaluate a simple treatment protocol for China in a real clinic setting.

Study design: In this study, newly identified uncontrolled hypertension or monotherapy for patients with substandard blood pressure are sequentially enrolled and monitored for blood pressure in the office and at home. Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group.

Study population: Men and Women aged 18-80 years (n=400) meeting the inclusion/exclusion criteria.

Randomization and treatment: Randomization was carried out on a machine numeric table, one center with a small value assigned to the usual care group and one with a larger number was assigned to the standard treatment group. In the usual treatment group, the doctor prescribes medication for patients, and advise the patient to take the medication on time and follow-up every 3 months. The standard treatment group was followed up monthly, Amlodipine 5 mg is preferred for selected patients, and amlodipine 5 mg + irbesartan 150mg is used for those who do not meet blood pressure targets after 4 weeks of treatment, aftre one month amlodipine 10mg + irbesartan 300mg is used for those who do not meet blood pressure targets, for those whose blood pressure is still not up to standard after 4 weeks will be treated with amlodipine 10mg + irbesartan 300mg + hydrochlorothiazide 12.5mg.

Follow up: 6 months. Sample size: a total of 400 patients should be enrolled in the combination. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in November 2024, Patients enrollment will be performed between Feburary 2025 to Feburary 2026.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Age 18-80 years; 2. Newly identified or monotherapy patients with uncontrolled clinical blood pressure; 3. Systolic blood pressure≥140 mmHg and/or diastolic blood pressure≥90 mmHg; 4. Agree to participate in the trial and sign the informed consent form. Exclusion criteria: 1. The arm circumference is too large or too small (\<17cm or \>42cm) ; 2. suspected or definite secondary hypertension; 3. Combined with eGFR \< 30 ml/min/1.73m2 or end-stage renal disease; 4. Cardiovascular and cerebrovascular events have occurred in the past 3 months, such as myocardial infarction, stroke, acute heart failure, causes Unstable angina pectoris, hospitalization or revascularization of coronary artery disease or bypass graft surgery; 5. Combined with liver damage: aspartate aminotransferase \[AST\] or alanine aminotransferase \[ALT\] or total bilirubin at 2 times or more of the upper limit of normal; 6. Concomitant physical diseases with survival expectations of less than 3 years, or tumors diagnosed in the past 2 years and requiring treatment; 7. The investigator assessed that participation in the study was unfavorable to the subject.

Primary outcome measure(s)

Control rate of clinical blood pressure — 6 months

Trial sites (1)

Facility	City	Region	Status
Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	China

More Shanghai Jiao Tong University School of Medicine trials in China

Autoimmune Hepatitis Cohort in China Recruiting

Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia Recruiting

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation Active, not recruiting

Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC Recruiting

Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes Starting soon

Other trials for the same condition

LLM-CoManage: Large Language Model-Enabled Co-Management of Hypertension, Diabetes, and Dyslipidemia Active, not recruiting

Clinical Analysis of the Antihypertensive Effect of Laparoscopic Peripheral Nerve Blockade of the Renal Artery in Patients With Retroperitoneal Disease and Hypertension Recruiting

Goal Commitment and Proactive Health Behavior in Chronic Disease Patients Recruiting

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation Active, not recruiting

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06790927 on ClinicalTrials.gov ↗ ← All trials in China